Prolonged therapy with ICSs has been associated with modulations in hormone secretion patterns, particularly affecting growth hormone release, which may lead to metabolic and cardiovascular complications, thereby exacerbating the impact of OSA [55]. Here, GH1 is linked to obstructive sleep apnea syndrome.